Sumitomo Pharma Co., Ltd.
4506
Classement en actions
#3137
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Prix de l'action
$12.86
Capitalisation boursière
$5.77B
Changement (1 jour)
4.48%
Changement (1 an)
15.98%
Pays
JP
Échange Sumitomo Pharma Co., Ltd. (4506)
Catégorie
Healthcare
Ratio P/E pour Sumitomo Pharma Co., Ltd. (4506)
Ratio P/E au October 2026 TTM : 6.54
Selon les derniers rapports financiers et le cours de l'action de Sumitomo Pharma Co., Ltd., le ratio P/E actuel (TTM) est de 6.54. À la fin de l’année 2024, le P/E de l’entreprise était de -0.51.
Historique du ratio P/E pour Sumitomo Pharma Co., Ltd. de 2005 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 6.54 | -46.61% |
| 2025 | 12.25 | -2,493.01% |
| 2024 | -0.51 | -88.14% |
| 2023 | -4.32 | -150.77% |
| 2022 | 8.51 | -37.53% |
| 2021 | 13.62 | -0.44% |
| 2020 | 13.68 | -39.08% |
| 2019 | 22.45 | 69.12% |
| 2018 | 13.28 | -47.29% |
| 2017 | 25.19 | 20.81% |
| 2016 | 20.85 | -43.08% |
| 2015 | 36.63 | 12.76% |
| 2014 | 32.48 | -50.45% |
| 2013 | 65.55 | 62.34% |
| 2012 | 40.38 | 120.26% |
| 2011 | 18.33 | 12.84% |
| 2010 | 16.25 | -0.10% |
| 2009 | 16.26 | 14.94% |
| 2008 | 14.15 | -36.09% |
| 2007 | 22.14 | -7.23% |
| 2006 | 23.87 | -3.68% |
| 2005 | 24.78 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 434.51% |
IN
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.